COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,724 Articles (22,502 medRxiv, 8,222 bioRxiv)

Most recent first Previous |  Page 1366: Articles 13651-13660  | Next

Effect of prophylactic use of intra-nasal oil formulations in the hamster model of Covid-19
Rizvi, Z. A., Tripathy, M. R., Sharma, N., Goswami, S., Srikanth, N., Shastry, J., Mani, S., Surjit, M., Awasthi, A., Dikshit, M.
10.1101/2021.06.25.449990 — Posted: 2021-06-28
A SARS-CoV-2 mini-genome assay based on negative-sense RNA to study replication inhibitors and emerging mutations
Vial, T., Oade, M. S., Russell, C. A., Eggink, D., te Velthuis, A. J. W.
10.1101/2021.06.28.450211 — Posted: 2021-06-28
Myeloid cell interferon responses correlate with clearance of SARS-CoV-2
Singh, D. K., Aladyeva, E., Das, S., Singh, B., Esaulova, E., Swain, A., Ahmed, M., Cole, J., Moodley, C., Mehra, S., Schlesinger, L., Artyomov, M., Khader, S. A., Kaushal, D.
10.1101/2021.06.28.450153 — Posted: 2021-06-28
A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2
Jiang, L., Driedonks, T., Lowman, M., Jong, W. S., van den Berg van Saparoea, H. B., Dhakal, S., Zhou, R., Caputo, C., Littlefield, K., Sitaris, I., Chen, M. W., Lima, G., Gololobova, O., Smith, B., Lane, A. P., Klein, S. L., Pekosz, A., Brayton, C. F., Luirink, J., Villano, J. S., Witwer, K. W.
10.1101/2021.06.28.450181 — Posted: 2021-06-28
Overcoming COVID-19 vaccine preferential bias in Europe: Is the end of the pandemic still foreseeable?
Adusei-Mensah, F., Inkum, I. E.
10.1101/2021.06.23.21259422 — Posted: 2021-06-28
Automated, miniaturized, and scalable screening of healthcare workers, first responders, and students for SARS-CoV-2 in San Diego County
Morgan, S. C., Aigner, S., Anderson, C., Belda-Ferre, P., De Hoff, P., Marotz, C. A., Sathe, S., Zeller, M., Ahmed, N., Audhya, X., Baer, N. A., Barber, T., Barrick, B., Batachari, L., Betty, M., Blue, S. M., Brainard, B., Buckley, T., Case, J., Castro-Martinez, A., Chacon, M., Cheung, W., Chong, L., Coufal, N. G., Crescini, E. S., DeGrand, S., Dimmock, D. P., Donofrio-Odmann, J. J., Eisner, E. R., Estaki, M., Franco Vargas, L., Freddock, M., Gallant, R. M., Galmozzi, A., Gao, N. J., Gilmer, S., Grzelak, E. M., Hakim, A., Hart, J., Hobbs, C., Humphrey, G., Ilkenhans, N., Jacobs, M., Kahn, C. A., Kapadia, B. K., Kim, M., Kurian, S., Lastrella, A. L., Lawrence, E. S., Lee, K., Liang, Q., Liliom, H., Lo Sardo, V., Logan, R., Machnicki, M., Magallanes, C. G., Mah, C. K., Malacki, D., Marina, R. J., Marsh, C., Martin, N. K., Matteson, N. L., Maunder, D. J., McBride, K., McDonald, B., McGraw, M., Meadows, A. R., Meyer, M., Morey, A. L., Mueller, J. R., Ngo, T. T., Nguyen, J., Nguyen, V., Nicholson, L. J., Nouri, A., Nudell, V., Nunez, E., O'Neill, K., Ostrander, R. T., Pantham, P., Park, S. S., Picone, D., Plascencia, A., Pratumchai, I., Quigley, M., Ragsac, M. F., Richardson, A. C., Robles-Sikisaka, R., Ruiz, C. A., Ryan, J., Sacco, L., Saraf, S., Seaver, P., Sewall, L., Smoot, E. W., Sweeney, K. M., Tekkatte, C., Tsai, R., Valentine, H., Walsh, S., Williams, A., Wu, M. Y., Xia, B., Yee, B., Zhang, J. Z., Andersen, K. G., Farnaes, L., Knight, R., Yeo, G. W., Laurent, L. C.
10.1101/2021.06.25.21257885 — Posted: 2021-06-28
SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men
Stirrup, O., Boshier, F. A. T., Venturini, C., Guerra-Assuncao, J., Alcolea-Medina, A., Becket, A. H., Charalampous, T., da Silva Filipe, A., Glaysher, S., Khan, T., Kulasegara-Shylini, R., Kele, B., Monahan, I. M., Mollett, G., Parker, M., Pelosi, E., Randell, P., Roy, S., Taylor, J. F., Weller, S. J., Wilson-Davies, E., Wade, P., Williams, R., COG-UK HOCI Variant Substudy consortium, , The COVID-19 Genomics UK (COG-UK) consortium, , Copas, A. J., Cutino-Moguel, T., Freemantle, N., Hayward, A. C., Holmes, A., Hughes, J., Mahungu, T. W., Nebbia, G., Partridge, D. G., Pope, C. F., Price, J. R., Robson, S. C., Saeed, K., de Silva, T. I., Snell, L. B., Thomson, E. C., Witney, A. A., Breuer, J.
10.1101/2021.06.24.21259107 — Posted: 2021-06-28
Macro-Level Drivers of SARS-CoV-2 Transmission: A Data-Driven Analysis of Factors Contributing to Epidemic Growth During the First Wave of outbreaks in the United States
Watts, M.
10.1101/2021.06.23.21259394 — Posted: 2021-06-28
Pre-activated anti-viral innate immunity in the upper airways controls early SARS-CoV-2 infection in children
Loske, J., Röhmel, J., Lukassen, S., Stricker, S., Magalhaes, V. G., Liebig, J., Chua, R. L., Thürmann, L., Messingschlager, M., Seegebarth, A., Timmermann, B., Klages, S., Ralser, M., Sawitzki, B., Sander, L. E., Corman, V. M., Conrad, C., Laudi, S., Binder, M., Trump, S., Eils, R., Mall, M., Lehmann, I.
10.1101/2021.06.24.21259087 — Posted: 2021-06-28
Short-term Outcomes in Children Recovered from Multisystem Inflammatory Syndrome associated with SARS-CoV-2 infection
Patnaik, S., Jain, M. K., Ahmed, S., Dash, A. K., P, R. K., Sahoo, B., Mishra, R., Behera, M. R.
10.1101/2021.06.23.21259292 — Posted: 2021-06-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).